Clinical trial · Observational
The clonoSEQ® Watch Registry
Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The 'Watch' Registry
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sufficient data collected.
Summary
Brief summary (as posted)
This is a prospective, multicenter, observational study of adult patients with a diagnosis of acute lymphoblastic leukemia (ALL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), or non-Hodgkin lymphoma (NHL). This study will enroll up to 528 patients in up to 50 sites in the United States and collect data with regard to use of the clonoSEQ MRD assay in the management of lymphoid malignancies.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia, Adult B-Cell | Adult B Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Non-hodgkin Lymphoma | Non-Hodgkin Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| clonoSEQ Assay | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- ALL
- description
- patients diagnosed with acute lymphoblastic leukemia
- interventionNames
- Diagnostic Test: clonoSEQ Assay
- label
- CLL
- description
- patients diagnosed with chronic lymphocytic leukemia
- interventionNames
- Diagnostic Test: clonoSEQ Assay
- label
- MM
- description
- patients diagnosed with multiple myeloma
- interventionNames
- Diagnostic Test: clonoSEQ Assay
- label
- NHL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients must be able to provide written informed consent 2. A decision has been made by the treating provider to use the clonoSEQ Assay as part of routine clinical care 3. Age ≥ 18 years; 4. Documented hematologic malignancy (any of the below): 1. MM 2. ALL (B and T-cell subtypes) 3. B-cell NHL (all sub types) 4. CLL 5. Other lymphoid malignancies (upon review and approval by study chair) Exclusion Criteria: Patients must not meet any of the following criteria in order to be enrolled into the study: 1. Concurrent enrollment in a clinical trial where treatment decisions and patterns are dictated per protocol 2. A decision has been made by the treating provider to not use the clonoSEQ Assay as part of routine clinical care
References
Publications (0)
Data not yet available